Celltrion Pharm, Inc. (KOSDAQ:068760)

South Korea flag South Korea · Delayed Price · Currency is KRW
49,300
+50 (0.10%)
Jun 5, 2025, 3:30 PM KST
-44.28%
Market Cap 2.14T
Revenue (ttm) 274.73B
Net Income (ttm) 26.03B
Shares Out 43.49M
EPS (ttm) 595.02
PE Ratio 82.85
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 72,178
Average Volume 64,007
Open 49,250
Previous Close 49,250
Day's Range 49,000 - 49,850
52-Week Range 44,500 - 98,095
Beta 1.40
RSI 61.53
Earnings Date n/a

About Celltrion Pharm

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. [Read more]

Sector Healthcare
Founded 1976
Employees 328
Stock Exchange KOSDAQ
Ticker Symbol 068760
Full Company Profile

Financial Performance

In 2020, Celltrion Pharm's revenue was 233.57 billion, an increase of 34.61% compared to the previous year's 173.51 billion. Earnings were 20.94 billion, an increase of 143.42%.

Financial Statements

News

There is no news available yet.